On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi), a new targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
How Was Taletrectinib Studied?
Taletrectinib was evaluated in two international clinical trials (TRUST-I and TRUST-II), involving patients whose lung cancer tested positive for the ROS1 gene change. The studies included both patients who had never received a ROS1-targeted treatment and those who had previously been treated with a ROS1 inhibitor.
- Among patients who had not received a ROS1 inhibitor before, about 85–90% responded to taletrectinib, and most responses lasted at least 12 months.
- Among patients who had already tried a ROS1 inhibitor, about 52–62% responded, with most responses lasting at least 6 months.
What Should Patients Know About Side Effects?
Taletrectinib is generally well-tolerated, with most side effects being manageable, such as mild liver enzyme changes and gastrointestinal symptoms. Importantly, it is designed to minimize neurological side effects compared to earlier drugs. The prescribing information for taletrectinib includes warnings about possible side effects, such as:
- Liver problems (hepatotoxicity)
- Lung inflammation (interstitial lung disease/pneumonitis)
- Heart rhythm changes (QTc interval prolongation)
- High uric acid levels (hyperuricemia)
- Muscle pain with increased muscle enzymes
- Bone fractures
- Potential harm to unborn babies
About Taletrectinib
Over time, many patients develop resistance to first-generation ROS1 inhibitors like crizotinib and entrectinib. Taletrectinib has demonstrated activity against tumors with resistance mutations, offering an option for those with limited alternatives. Taletrectinib is designed specifically for people with ROS1-positive cancer and is able to reach and work in the brain (CNS-active). Taletrectinib is a next-generation ROS1 inhibitor, meaning it is a more advanced and selective treatment that blocks the ROS1 protein, which helps slow or stop the growth of cancer cells.
Ongoing studies continue to follow patients long-term, but current evidence supports taletrectinib as a potential best-in-class therapy for ROS1-positive cancers. If you have ROS1-positive NSCLC, talk to your oncologist to about the risks and benefits of all treatment options including taletrectinib.
Reference
Maurice Pérol et al. Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST. JCO 43, 1920-1929(2025).
Pérol M, Li W, Pennell NA, et al. Pooled efficacy and safety from 2 pivotal phase 2 trials of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer. Presented at: 2024 ESMO Congress; September 13-17, 2024; Barcelona, Spain. Poster 1289.
Li W, Xiong A, Yang N, et al. Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non–small cell lung cancer: the phase II TRUST-I study. J Clin Oncol. 2024;42(22):2660-2670. doi:10.1200/JCO.24.00731
Liu G, Yang N, Choi CM, et al. Efficacy and safety of taletrectinib in patients with ROS1+ non-small cell lung cancer: the global TRUST-II study. Presented at: 2024 IASLC World Conference on Lung Cancer; September 7-10, 2024; San Diego, California. Abstract MA06.03.
